Browse All

Current Filters

CLEAR FILTER x

TITLE

Imaging Outcomes of a Dopaminergic Neuronal Cell Therapy for Parkinson’s Disease: 18-month Results from a Phase 1 Study of Bemdaneprocel

Author:Henchcliffe, Claire   Ma, Yilong   Sarva, Harini   Lozano, Andres   Fasano, Alfonso   Kalia, Suneil   Yu, Kenny Kwok Hei   Brennan, Cameron   Jennings, Nicki   stemple, Whitney   Abid, Nauman   Yountz, Marcus   Enayetallah, Ahmed   Lampron, Antoine   Tabar, Viviane   Eidelberg, David   

Session Name:S30: Movement Disorders: Clinical Trials in Movement Disorders  

Topic:Movement Disorders  

Program Number:S30.005  

Author Institution:University of California, Irvine, Orange, CA  Feinstein Institute for Medical Research, Manhasset, NY  Weill Cornell Medical Center, New York, NY  Toronto Western Hosp, Toronto, ON, Canada  Toronto Western Hospital - U of Toronto, Toronto, ON, Canada  University of Toronto, Toronto, ON, Canada  Memorial Sloan Kettering Cancer Center, New York, NY  BlueRock Therapeutics LP, Cambridge, MA  BlueRock Therapeutics, Cambridge, MA  

Neurocinema: Expanding a Multimodal Approach Across the Continuum of Medical Education

Author:Baveja, Shivali   Nguyen, Hoang-Lan   Attaripour, Sanaz   Henchcliffe, Claire   

Session Name:P7: Education, Research, and Methodology: Career Development and Physician Well-being  

Topic:Education, Research, and Methodology  

Program Number:P7.004  

Author Institution:University of California, Irvine, Orange, CA  University of California, Irvine, Irvine, CA  

Non-motor Effects of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study

Author:Sarva, Harini   Henchcliffe, Claire   Lozano, Andres   Kalia, Suneil   Yu, Kenny Kwok Hei   Brennan, Cameron   York, Michele   stemple, Whitney   Abid, Nauman   Yountz, Marcus   Enayetallah, Ahmed   Lampron, Antoine   Tabar, Viviane   

Session Name:P9: Movement Disorders: Parkinson's Disease Clinical Trials  

Topic:Movement Disorders  

Program Number:P9.001  

Author Institution:Weill Cornell Medical Center, New York, NY  University of California, Irvine, Orange, CA  Toronto Western Hosp, Toronto, ON, Canada  University of Toronto, Toronto, ON, Canada  Memorial Sloan Kettering Cancer Center, New York, NY  Baylor College of Medicine, Houston, TX  BlueRock Therapeutics, Cambridge, MA  

Safety, Tolerability, and Clinical Assessment of Bemdaneprocel for Parkinson’s Disease: 18-month Results from a Phase 1 Study

Author:Henchcliffe, Claire   Sarva, Harini   Lozano, Andres   Fasano, Alfonso   Kalia, Suneil   Yu, Kenny Kwok Hei   Brennan, Cameron   stemple, Whitney   Abid, Nauman   Yountz, Marcus   Enayetallah, Ahmed   Lampron, Antoine   Tabar, Viviane   

Session Name:P9: Movement Disorders: Parkinson's Disease Clinical Trials  

Topic:Movement Disorders  

Program Number:P9.007  

Author Institution:University of California, Irvine, Orange, CA  Weill Cornell Medical Center, New York, NY  Toronto Western Hosp, Toronto, ON, Canada  Toronto Western Hospital - U of Toronto, Toronto, ON, Canada  University of Toronto, Toronto, ON, Canada  Memorial Sloan Kettering Cancer Center, New York, NY  BlueRock Therapeutics, Cambridge, MA